News|Articles|May 29, 2026

ASCO 2026: Key Genitourinary Oncology Trials to Watch For

Fact checked by: Roman Fabbricatore, Russ Conroy

Saum Ghodoussipour, MD, suggested that advances in liquid biopsy tracking, next-generation ADCs, and organ-sparing approaches may be featured at ASCO 2026.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature practice-changing clinical data across multiple oncology subspecialties. For genitourinary (GU) oncology clinicians, the upcoming presentations promise to deliver deep discussions on therapeutic sequencing, patient-reported outcomes, and novel mechanistic strategies.

Related to this article

Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.

October 16th, 2026

Addressing Prospective Data Gaps for Radiotherapy Use in Multiple Myeloma

Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.

There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.

October 16th, 2026

Using Radiotherapy Strategically Alongside CAR T, Bispecifics in Myeloma

There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.

October 15th, 2026

Proton Therapy Tied to Less Hypothyroidism After Supraclavicular Breast RT

Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.

Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.

October 14th, 2026

The Promise of CERVINO, MajesTEC-3, and EXCALIBER-RRMM in Multiple Myeloma

Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.

Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.

October 14th, 2026

What Data Should Radiation Oncologists Know From ASTRO 2026?

Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.

Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.

October 13th, 2026

How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?

Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.

“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.

October 9th, 2026

Weighing the Promise and Trade-Offs of CAR NK Cell Therapy for Cancer

“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

October 9th, 2026

Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.